Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

HPV Vaccination & Maternal and Infant Outcomes

Obstet Gynecol; 2017 Sep; Lipkind, et al

When inadvertently administered in pregnancy or during the periconceptional periods, quadrivalent human papillomavirus vaccine (4vHPV) was not associated with adverse pregnancy or birth outcomes, a recent study found. The retrospective, observational cohort study included 92,579 potentially eligible pregnant women, 720 of whom received 4vHPV during the periconceptional period, 638 during pregnancy, and 8,196 during the comparison period. Researchers found:

  • Administration of 4vHPV during pregnancy was not associated with increased risk of adverse obstetric events, birth outcomes.
  • Preterm birth occurred in 7.9% of pregnancies with vaccine exposures during pregnancy vs 7.6% of pregnancies with vaccination in the comparison period.
  • Major structural birth defects were diagnosed in 2.0% of pregnancies with vaccine exposure during pregnancy vs 1.8% of pregnancies with vaccine exposure during the comparison period.
  • Results were similar for 4vHPV exposure during the periconceptional period.


Lipkind HS, Vazquez-Benitez G, Nordin JD, et al. Maternal and infant outcomes after human papillomavirus vaccination in the periconceptional period or during pregnancy. Obstet Gynecol. 2017;130(3)599-608. doi:10.1097/AOG.0000000000002191.